Cytokinetics Inc To Host Virtual Investor & Analyst Day Transcript
Good morning. I'm Diane Weiser, Senior Vice President, Corporate Communications and Investor Relations. I'm pleased to welcome you to new horizons and hypercontractility. Our 2023 Virtual Investor and Analyst Day. Over the course of the next few hours, we plan to review the broad development program for Aficamten and outline commercial readiness for its potential approval and launch in obstructive hypertrophic cardiomyopathy as well as present new preclinical data for CK-586, a cardiac myosin inhibitor in development for the potential treatment of patients with heart failure with preserved ejection fraction.
Today's slides are available for download on the right side of the webcast. We will be hosting a Q&A session at the end of our program today. (Operator Instructions) Next slide.
Before I continue, please note that portions of the following discussion, including our responses to questions, contain statements that relate to future events and performance rather than historical facts and constitute
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |